<?xml version="1.0"?>
<root>
  <statistics>
    <p_e_ratio>N/A</p_e_ratio>
    <peg_ratio>0.0</peg_ratio>
    <earnings_per_share>-1.02</earnings_per_share>
    <ebitda>-120800000.0</ebitda>
    <eps_estimate_current_year>-0.81</eps_estimate_current_year>
    <eps_estimate_next_quarter>-0.09</eps_estimate_next_quarter>
    <fifty_day_moving_average>11.82</fifty_day_moving_average>
    <fifty_two_week_high>14.93</fifty_two_week_high>
    <fifty_two_week_low>4.52</fifty_two_week_low>
    <percent_change_from_200_day_moving_average>-0.2771</percent_change_from_200_day_moving_average>
    <percent_change_from_50_day_moving_average>-0.3173</percent_change_from_50_day_moving_average>
    <shares_owned>N/A</shares_owned>
    <short_ratio>11.85</short_ratio>
    <two_hundred_day_moving_average>11.16</two_hundred_day_moving_average>
    <volume>8083153.0</volume>
    <market_cap>1060000000.0</market_cap>
    <price_to_sales_ttm>389.33</price_to_sales_ttm>
    <price_to_book_mrq>11.42</price_to_book_mrq>
    <roa_ttm>-0.6811</roa_ttm>
    <roe_ttm>-1.8572</roe_ttm>
    <shares_outstanding>130889999.99999999</shares_outstanding>
    <pcnt_held_by_insiders>0.0212</pcnt_held_by_insiders>
    <pcnt_held_by_institutions>0.509</pcnt_held_by_institutions>
    <pcnt_short_of_float>0.327</pcnt_short_of_float>
    <operating_cash_flow_ttm>13920000.0</operating_cash_flow_ttm>
    <levered_cash_flow_ttm>-57170000.0</levered_cash_flow_ttm>
    <book_value_per_share_mrq>0.72</book_value_per_share_mrq>
    <next_earnings_announcement_date/>
    <sector>Healthcare</sector>
    <industry>Biotechnology</industry>
    <company_name>ZIOPHARM Oncology, Inc.</company_name>
  </statistics>
</root>
